Science
tience technology.
platform for Multiple high-value indications
Tience technology
Tience® technology enables the development of multiple regenerative injectables across aesthetic and reconstructive indications, including:
- Volume restoration
- Scar treatments
- Post-surgical regeneration
- Soft tissue defects
- Skin quality improvement
Each indication builds on the same underlying biology, manufacturing infrastructure, and regulatory backbone — allowing capital-efficient pipeline expansion without rebuilding from scratch.
This platform approach creates long-term optionality for both internal development and strategic partnering.
Clinically validated platform technology
Tience® technology is commercially used in Finland and Sweden by ~40 leading healthcare clinics.
Tience® technology is first-of-its-kind, cell-free tissue product that improves skin functionality by harnessing the regenerative potential of human adipose tissue in a ready-to-use format.
Using only bioactive substances, Tience® naturally supports the skin repair and renewal processes, delivering long-lasting improvements in skin condition, structure, and elasticity. The results are comparable to traditional autologous methods — without their complexity, variability, or procedural burden.
For healthcare professionals, Tience® offers an efficient, sustainable, and clinically validated solution for treating therapeutic and aesthetic indications.
Research
Our current research is addressing a major unmet need in skin and soft-tissue treatment: enabling the body to support regenerating damaged or aging tissue in a safe, scalable, and minimally invasive way — not by temporarily “filling” defects, but by restoring function, structure, and biological health.
Today’s aesthetic solutions largely rely on synthetic fillers or invasive autologous procedures that provide short-term results and come with trade-offs in safety, scalability, or natural outcomes. Linio Biotech is pioneering a fundamentally different approach: supporting skin and soft tissue regeneration, delivered in a ready-to-use injectable format.
Research
Our current research is addressing a major unmet need in skin and soft-tissue treatment: enabling the body to support regenerating damaged or aging tissue in a safe, scalable, and minimally invasive way — not by temporarily “filling” defects, but by restoring function, structure, and biological health.
Today’s aesthetic solutions largely rely on synthetic fillers or invasive autologous procedures that provide short-term results and come with trade-offs in safety, scalability, or natural outcomes. Linio Biotech is pioneering a fundamentally different approach: supporting skin and soft tissue regeneration, delivered in a ready-to-use injectable format.
A regenerative alternative to conventional aesthetic solutions
Our research targets conditions where current solutions fall short, including:
- Soft-tissue volume loss
- Scarring and acne scars
- Skin damage and structural defects
- Age-related skin deterioration
Rather than offering cosmetic masking, our goal is to shift the paradigm — from artificial volume replacement to tissue regeneration. This approach restores both appearance and function, while remaining clinically scalable and compatible with modern aesthetic practice.
Our long-term vision is to set a new standard in aesthetic and regenerative medicine by introducing innovations that activate the body’s own repair and rebuilding mechanisms — delivering natural, durable outcomes without autologous cell therapies or surgery.
Investigational Product
We are developing a hybrid injectable leveraging our proprietary Tience® technology, with an initial focus on volume restoration.
The product is designed to:
- Provide an immediate lifting effect
- Subsequently support endogenous soft-tissue formation
- Deliver natural, long-lasting results aligned with patient and physician expectations
This dual mechanism — instant correction combined with biological regeneration — differentiates our approach from conventional fillers and positions the product within the fastest-growing segment of medical aesthetics.
Scientific validation and development progress
We have achieved proof-of-concept and demonstrated promising pre-clinical results that confirm the mode of action underlying our approach.
Our ongoing research program focuses on:
- Translating adipose tissue research insight into scalable products
- Strengthening mechanistic understanding of tissue regeneration
- Advancing towards CE-marking and FDA approval
Cutting-edge science underpins every step of our development — reducing technical risk while expanding long-term platform potential.
where we are today
- Investigational product in development, progressing towards MDR and FDA regulatory pathways
- Vertically integrated R&D and manufacturing through our own licensed tissue establishment in Tampere, Finland
- IP-protected platform technology built on decades of adipose tissue research
- Strong clinical foundation, including post-market data from nearly 2,000 treated patients
- Growing commercial traction with Tience® and expanding physician partnerships, enabling the collection of globally unique real-world data
- Clear roadmap towards value-creating inflection points relevant for strategic partners and investors in medial aesthetics
-
-
-
-
